# Project-005

> **NIH NIH UL1** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $436,256

## Abstract

The primary goal of the Hub Research Capacity program is to support innovative research and to provide the
requisite tools for investigators to perform safe, high quality translational research. As outlined in the RFA, this
component of the CTSA will focus on Integrating Special Populations (ISP) along with Participant and Clinical
Interactions (PCI).
Our ISP core has extensive resources for performing translational research in various age groups including but
not limited to children, older adults, pregnant women and neonates (maternal-fetal medicine), as well as
Hispanic populations. Additionally, UTMB has tremendous expertise for investigating rare, orphan diseases
such as porphyria, mast cell disease etc. and research on the current US epidemic, opiate use and addictive
behaviors (Optional HUB). We are exclusively equipped with a state-of-the-art vaccine development center as
a critical arm of preventative care. Our Aim for ISP, will capitalize on existing individual program strengths to
collectively broaden our outreach in multicenter trials and underserved communities. The ISP core will be
intimately linked with Network Capacity and Informatics.
The PCI core will focus its efforts on clinician research education. Specifically, on novel methods to enhance
the safety and efficiency for conducting high quality translational research. Moving forward (Aims), clinical trials
will be augmented by integrating study coaches, training and support for new clinical studies as well as provide
investigators guidance to one of our new satellite studios. Working with Informatics Data Coordinating Center,
the PCI core will provide quality control component for new training, monitoring and regulatory aspects for
multi-site clinical trials. Additionally, UTMB continues to grow into a larger community area. Towards this end,
we will extend UTMB’s Clinical Research Center (CRC) footprint and its human research safety program. To
help accomplish these aims, the PCI core will utilize the Office of Clinical Research, the Clinical Research
Center (CRC) as well as have strong links with Translational Endeavors and Workforce Development.

## Key facts

- **NIH application ID:** 10141323
- **Project number:** 5UL1TR001439-07
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** Randall J Urban
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $436,256
- **Award type:** 5
- **Project period:** 2015-08-18 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10141323

## Citation

> US National Institutes of Health, RePORTER application 10141323, Project-005 (5UL1TR001439-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10141323. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*